Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

rovalpituzumab tesirine

An antibody-drug conjugate (ADC) containing an antibody (SC16) directed against an as of yet undisclosed protein and conjugated to the cytotoxic agent D6.5, with potential antineoplastic activity. Upon administration, the antibody moiety of rovalpituzumab tesirine selectively binds to the target on tumor cell surfaces. Upon internalization, the D6.5 moiety is released and causes DNA damage, which may result in the inhibition of proliferation of tumor cells that overexpress this target.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-SC16 ADC SC16LD6.5
antibody-drug conjugate SC16LD6.5
Rova-T
Code name:SC16LD6.5
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search